Brief: Aelis Farma Recruits First Patient For Aef0217 Trial In Down Syndrome

Aelis Farma SA

16/12/2022 06:02

Dec 16 (Reuters) - AELIS FARMA SA  AELIS.PA :
    * AELIS FARMA ANNOUNCES THE RECRUITMENT OF THE FIRST PATIENT
FOR
THE PHASE 1/2 CLINICAL TRIAL OF ITS DRUG CANDIDATE AEF0217 FOR
THE TREATMENT OF COGNITIVE DISORDERS IN DOWN SYNDROME
    * TRIAL SHOULD INCLUDE AROUND 45 PARTICIPANTS WITH DOWN
SYNDROME
(TRISOMY 21) AND SHOULD BE COMPLETED IN Q2 OF 2023
    * MAIN OBJECTIVE OF THE TRIAL IS TO ASSESS THE SAFETY AND
ABSORPTION OF AEF0217 AND IT COULD ALSO PROVIDE THE FIRST
INDICATIONS OF ACTIVITY AS A TREATMENT FOR THE COGNITIVE
IMPAIRMENTS OF DOWN SYNDROME
    * THESE POSITIVE RESULTS ALLOW NOW TO ADMINISTER AEF0217 TO
PEOPLE
WITH DOWN SYNDROME

Source text for Eikon:  ID:nBw3QgTGta 
Further company coverage:  AELIS.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))